Benzinga | Oct 12, 2020 07:10AM EDT

Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting

* New data demonstrate a sustained patient benefit following SER-109 administration with a highly statistically significant 31.1% absolute reduction in the rate of C. difficile infection recurrence over 12 weeks, compared to placebo --

* Additional new findings show similar SER-109 efficacy across stratified age groups and prior antibiotic treatment regimen cohorts --

* Well tolerated, with a safety profile comparable to placebo --

* SER-109 open label study enrolling individuals with recurrent C. difficile infection --